Skin Cancer

April 11th 2025

Christine Barrett, PharmD, BCOP, addressed advances in the treatment of stage III melanoma that provide the potential to improve long-term outcomes by enhancing immune response, tailoring surgical approaches, and refining patient selection strategies.

February 25th 2025

The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.

February 25th 2025

Immunotherapy pioneer James P. Allison, PhD, revolutionized cancer treatment by discovering immune checkpoint blockade, leading to significant advances in survival rates and ongoing efforts to optimize immuno-oncology strategies.

February 24th 2025

Advancements in neoantigen vaccines and immunotherapy are transforming cancer treatment by leveraging genomic sequencing to overcome tumor heterogeneity and therapeutic resistance.